Over 158 applications for generic products pending with USFDA for approval: Lupin

Sharing information with company's shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company's US business stabilised last fiscal and saw an increase of 5 per cent on the back of products like Levothyroxine and Oseltamivir.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news